Opens in a new tab
Tuesday, 17 November 2026
EVIDENCE. INTERPRETED.
Pharmacally

Narcolepsy

Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.

Advertisement · Remove ads
970 × 90

Latest in Narcolepsy

5 stories · every one Fact-Checked
The U.S. FDA has granted Fast Track designation to Lundbeck's investigational oral orexin 2 receptor agonist Lu AH69593 for narcolepsy. The therapy, currently in Phase 1b development, targets the orexin pathway to restore wakefulness and improve sleep-wake regulation, offering a potential disease-focused approach for patients with persistent excessive daytime sleepiness.Health TidingsFDA Grants Fast Track Status to Oral Orexin 2 Agonist Lu AH69593 for NarcolepsyThe U.S. FDA has granted Fast Track designation to Lundbeck’s investigational oral orexin 2 receptor agonist Lu AH69593 for narcolepsy.24 Jul 2026 · 3 min read
Fact-Checked
Takeda's ORZEYFUL (oveporexton), the first oral orexin receptor 2 agonist approved in China for treating narcolepsy type 1 in adolescents and adults.New Drug ApprovalChina Approves Takeda’s ORZEYFUL for Narcolepsy Type 1China’s NMPA has approved Takeda’s ORZEYFUL (oveporexton) for adolescents aged 16 years and older and adults with narcolepsy type 1.23 Jul 2026 · 4 min read
Fact-Checked
Takeda's ORZEYFUL (oveporexton), the first oral orexin receptor 2 agonist approved in China for treating narcolepsy type 1 in adolescents and adults.Clinical TrialsAlixorexton Shows Sustained Wakefulness and Daytime Sleepiness Benefits for Up to Nine Months in NarcolepsyAlkermes has reported positive interim long-term extension data showing alixorexton maintained clinically meaningful improvements in wakefulness, excessive daytime sleepiness, cognition, and fatigue for up to nine months in…13 Jul 2026 · 4 min read
Fact-Checked
image_ec0b97ddClinical TrialsJazz Highlights New Xywav Data Showing Cardiometabolic Benefits and Personalized Dosing in Narcolepsy and Idiopathic HypersomniaLate-breaking SLEEP 2026 data highlight Xywav’s potential to improve cardiometabolic risk markers and support individualized dosing strategies across narcolepsy and idiopathic hypersomnia treatment settings.17 Jun 2026 · 4 min read
Fact-Checked
Takeda_JP_1Clinical TrialsOveporexton Improves Daily Functioning and Sleep in Narcolepsy Type 1Phase 3 data presented at SLEEP 2026 show Takeda’s oveporexton significantly improved daily functioning, cognition, and sleep quality in narcolepsy type 1.16 Jun 2026 · 3 min read
Fact-Checked
Page 1 of 1